These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...
The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 — CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...
This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study Boston, MA –November 11, 2020: CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study,...
BOSTON, Oct. 3, 2019 /PRNewswire CSA Medical, Inc., presented positive 12-month results of its feasibility study for the RejuvenAir Metered Cryospray™ system yesterday at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain. In the...
Published by MassDevice Medical Network CSA Medical said today that results of its feasibility study into the RejuvenAir metered cryospray system showed improved quality of life in patients who have chronic obstructive pulmonary disease with chronic bronchitis. The...
CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.